You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
ANTI-CARDIOLIPIN AB |
||
ORDERING INFORMATION: | ||
Sunquest Test Code: |
CARDAB Geisinger Epic Procedure Code: 86147 Geisinger Epic ID: 7283 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum (preferred) or sodium citrate plasma. | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
2.7 mL blue-top (3.2% sodium citrate) tube
|
|
Specimen required: |
0.5 mL serum; minimum 0.2 mL | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow to clot. Centrifuge and submit 0.5 mL serum. | |
Transport temperature: |
Refrigerated (preferred). Room temperature (stable 8 hours) and frozen specimens also acceptable. | |
Specimen stability: |
Room temperature: 8 hours. 2-8°C: 48 hours. Frozen: 6 months. | |
Rejection criteria: |
Specimen stability exceeded; specimen grossly hemolyzed. | |
TEST DETAILS |
||
Reference interval: |
Cardiolipin IgG (CARDG)< 15 GPL units = Negative. Cardiolipin IgM (CARDM) < 12.5 MPL units = Negative. Cardiolipin IgA (CARDA)< 12 APL units = Negative. |
|
Additional information: |
Sodium citrate plasma has been validated for use with this assay for those patients ordered for Anti-Lupus Coagulation panels (LUPACP or LUPACC) without an available serum sample. | |
CPT code(s): |
86147 x 3 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Cardiolipin Antibody IgG, Cardiolipin Antibody IgM, Cardiolipin Antibody IgA | |
Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
|
Synonyms: |
Anticardiolipin antibody panel Antiphospholipid antibody panel Antiphospholipid AB ACA antibody panel, ACL antibody panel Cardiolipin antibody
|
|
Clinical significance: |
The presence of cardiolipin antibodies when used in conjunction with clinical findings and other laboratory tests can aid in assessing the risk of thromboembolic disease in patients with systemic lupus erythematosus (SLE) or primary anti-phospholipid syndrome (APS). | |
Doctoral Director(s:) |
Stacy Kenyon, PhD, DABCC Hoi-Ying Elsie Yu, PhD, DABCC |
|
| Review Date: | 10/24/2018 | |